22 February 2010
Katie McQue
The EU's CHMP has refused to endorse the approval of Basilea Pharmaceutica's intravenous broad-spectrum cephalosporin antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and skin structure infections.
The decision has prompted Cilag (a
Johnson & Johnson subsidiary)...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Could another biosimilars fight be a brewin'?
- Chroma/CTI plan tosedostat PhIII to avoid AML trap that caught Vion, J&J and Genzyme
- Poland's new law fixes prices and trade mark-ups of reimbursed drugs
- Forest to acquire Clinical Data Inc to add antidepressant Viibryd to portfolio
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
